|Videos|November 10, 2022
Challenges Associated With Insomnia Treatments
Author(s)Charlene Gamadelo, MD
Charlene Gamadelo, MD, describes the different categories of FDA approved treatments for insomnia along with challenges associated with these treatments.
Advertisement
Episodes in this series
Advertisement
Related to this article
In a pivotal phase 3 study, once-daily tasimelteon 20 mg shifted sleep onset 37.1 minutes earlier than placebo in adults with delayed sleep-wake phase disorder.
Tonic motor activation therapy was associated with reductions in RLS severity, along with tolerable reductions in dopamine agonist dosing, in adults with medication-refractory RLS.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Approves Tavapadon for the Treatment of Parkinson Disease
2
FDA Accepts Fenebrutinib NDA Under Priority Review for Relapsing and Primary Progressive MS
3
Phase 4 OCTAGON Trial to Test Rapid Steroid Taper With Ravulizumab
4
PETUNIA Study to Track Nipocalimab Use in Pregnancy
5